Forte Biosciences, Inc. (FBRX)

76.97 +0.02 (+0.03%) USD  |  NASDAQ  |  Aug 25, 11:22
More

Forte Biosciences Revenue Estimates for Current Fiscal Year

Revenue Estimates for Current Fiscal Year Chart

View Revenue Estimates for Current Fiscal Year for FBRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Current Fiscal Year Chart
Start Trial

Historical Revenue Estimates for Current Fiscal Year Data

View and export this data back to 2024. Start Trial.
Date Value
July 27, 2026 --
July 09, 2026 --
May 13, 2026 --
May 11, 2026 --
April 06, 2026 --
April 02, 2026 --
April 01, 2026 --
March 31, 2026 --
February 20, 2026 --
January 19, 2026 --
December 31, 2025 --
November 25, 2025 --
November 17, 2025 --
November 14, 2025 --
August 18, 2025 --
August 16, 2025 --
August 15, 2025 --
June 30, 2025 --
Date Value
June 24, 2025 --
June 05, 2025 --
May 16, 2025 --
May 15, 2025 --
April 03, 2025 --
April 01, 2025 --
March 31, 2025 --
January 21, 2025 --
December 31, 2024 --
December 04, 2024 --
November 15, 2024 --
September 03, 2024 --
August 19, 2024 --
August 15, 2024 --
May 29, 2024 --
May 16, 2024 --
May 14, 2024 --
April 08, 2024 --

Revenue Estimates for Current Fiscal Year Range, Past 5 Years

View Revenue Estimates for Current Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Current Fiscal Year Benchmarks

View Revenue Estimates for Current Fiscal Year Benchmarks
Start Trial
argenx SE Upgrade
ACADIA Pharmaceuticals, Inc. Upgrade
Alnylam Pharmaceuticals, Inc. Upgrade
Anika Therapeutics, Inc. Upgrade
Savara, Inc. Upgrade

Revenue Estimates for Current Fiscal Year Related Metrics

EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade